Test Price
2,800 AED✅ Home Collection Available
SCN1B Gene Brugada Syndrome Type 5 Next‑Generation Sequencing (NGS) Genetic Test in UAE
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity – ISO‑certified NGS laboratory processing ensures near‑perfect analytical accuracy for SCN1B variant detection.
- VIP Mobile Phlebotomy – Hospital‑grade home collection (8 AM–11 PM) with cold‑chain transport, preserving DNA integrity from FTA cards, whole blood, or extracted DNA.
- Post‑Test Clinical Guidance – Complimentary tele‑consultation to interpret results, discuss risk stratification, and plan cardiogenetic follow‑up.
- Insurance Support – Direct billing verification via WhatsApp at +971 54 548 8731; we confirm coverage before sample collection.
Test Overview & Methodology
The SCN1B gene test identifies pathogenic variants linked to Brugada syndrome type 5, a potentially fatal cardiac channelopathy characterised by ST‑segment elevation in right precordial leads and elevated risk of ventricular arrhythmia. Our NGS assay sequences the complete coding region with copy‑number variation analysis, delivering a definitive molecular diagnosis within 3–4 weeks.
| Feature | Our Test (NGS – SCN1B) | Closest Alternative (Single‑Gene or Panel) |
|---|---|---|
| Analytical Sensitivity | >99.9% (deep coverage >100×) | ~95–98% (Sanger sequencing, limited to known exons) |
| Methodology | Next‑Generation Sequencing (NGS) + CNV detection | Sanger sequencing or targeted panel without copy‑number analysis |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks (often batch‑dependent) |
| Pre‑Test Genetic Counselling | Included (pedigree charting + informed consent) | Optional / referral‑based |
| Report Interpretation | Clinician‑guided tele‑consultation | Standard lab report only |
Physician Insight & Safety Protocols
“A genetic result is not a crystal ball; it must be weighed against your personal and family history, electrocardiogram, and phenotype. Our team, led by Lina Osama Zaki Quteineh (DHA: 9294403), ensures every SCN1B report is clinically contextualised to prevent unnecessary anxiety and to guide evidence‑based management. We never recommend altering cardiac medications based solely on a genotype; always consult your treating cardiologist.”
Advisory Notice
⚠ Do not discontinue any prescribed antiarrhythmic or beta‑blocker without direct instruction from your doctor. Abrupt cessation may provoke life‑threatening arrhythmias.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria for Sample Collection
- Recent major surgery or blood transfusion (≤2 weeks)
- Active febrile illness or systemic infection
- Inability to provide informed consent or pedigree history
- Minors without legal guardian (per UAE law)
- Unstable haemodynamic state
Emergency Red Flags (Seek Immediate Care)
- Syncope (fainting) without warning
- Nocturnal agonal respiration
- Family history of sudden cardiac death <40 years
- Recurrent palpitations with chest pain
- ECG type 1 Brugada pattern + symptomatic
Patient FAQ & Clinical Guidance
1. How accurate is the SCN1B NGS test for Brugada syndrome type 5, and what makes it the preferred diagnostic choice in UAE?
Our SCN1B NGS test delivers over 99.9% analytical sensitivity, detecting single‑nucleotide variants, small insertions/deletions, and copy‑number changes across all coding exons with a validated 3‑week turnaround.
2. What sample types are accepted, and how is the home collection service conducted?
We accept whole blood, extracted DNA, or a single drop of dried blood on an FTA card; a licensed phlebotomist arrives at your home in a GPS‑tracked vehicle, maintains cold‑chain transport, and completes the process in under 15 minutes.
3. Is genetic counselling required before the test, and what does the post‑test support include?
A pre‑test counselling session is mandatory to draw a three‑generation pedigree and obtain informed consent; after results, a DHA‑licensed clinician explains variant significance and recommends cardiology follow‑up.
UAE Regulatory & Data Privacy Adherence
Data Protection & Security
All genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient confidentiality is protected throughout the testing lifecycle, including encrypted transmission and secure disposal of biological material.
Clinical & Logistical Metadata
| Test Name | SCN1B Gene Brugada Syndrome Type 5 Next‑Generation Sequencing (NGS) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or dried blood spot (FTA card) |
| Methodology Used | Next‑Generation Sequencing (NGS) with copy‑number variation (CNV) analysis |
| ICD-10-CM Code | I49.81 (Brugada syndrome) |
| LOINC Code | 48032-3 (Gene mutations detected in Specimen by Sequencing) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians